Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

  • NREC Code:

    21-NREC-CT-002

  • Decision:

    Favourable

  • Meeting Date:

    02/06/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Orla Hardiman

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Cytokinetics, Inc.

Scroll to Top